Invention Grant
- Patent Title: Bacteria engineered to treat disorders in which oxalate is detrimental
-
Application No.: US15755836Application Date: 2016-08-31
-
Publication No.: US11273184B2Publication Date: 2022-03-15
- Inventor: Vincent Isabella , Dean Falb , Cami Leigh Anderson , Paul Miller , Yves Millet , Jonathan Kotula
- Applicant: Synlogic Operating Company, Inc.
- Applicant Address: US MA Cambridge
- Assignee: Synlogic Operating Company, Inc.
- Current Assignee: Synlogic Operating Company, Inc.
- Current Assignee Address: US MA Cambridge
- Agency: McCarter & English, LLP
- Agent Marcie B. Clarke
- International Application: PCT/US2016/049781 WO 20160831
- International Announcement: WO2017/040719 WO 20170309
- Main IPC: A61K35/74
- IPC: A61K35/74 ; C07K14/195 ; C12N1/00 ; A61P3/00 ; C12N15/52 ; C12N15/70
Abstract:
The present invention provides recombinant bacterial cells comprising at least one heterologous gene encoding at least one oxalate catabolism enzyme. In another aspect, the recombinant bacterial cells further comprise at least one heterologous gene encoding an importer of oxalate. The invention further provides pharmaceutical compositions comprising the recombinant bacteria, and methods for treating disorders in which oxalate is detrimental, such as hyperoxaluria, using the pharmaceutical compositions of the invention.
Public/Granted literature
- US20180325963A1 BACTERIA ENGINEERED TO TREAT DISORDERS IN WHICH OXALATE IS DETRIMENTAL Public/Granted day:2018-11-15
Information query
